Volume 9, Number 9—September 2003
Research
Ehrlichia chaffeensis Infections among HIV-infected Patients in Human Monocytic Ehrlichiosis–Endemic Area
Thomas R. Talbot*
, James A. Comer†, and Karen C. Bloch*
, James A. Comer†, and Karen C. Bloch*
Table
Baseline characteristics of study cohort of HIV-positive persons residing in Tennesseea
| Characteristic | N (% or range) |
|---|---|
| Age (mean, y) |
38.8 (21–75) |
| Sex |
|
| Male |
107 (80.5%) |
| Female |
26 (19.5%) |
| Baseline CD4 count (median, cells/mm3) |
370 (6–1,200) |
| Baseline viral load (median, copies/dL) |
1,003 (<400–>750,000) |
| On prophylaxis |
|
| HAART |
122 (91.7%) |
| OI prophylaxis |
70 (52.6%) |
| PCP prophylaxisb |
66 (49.6%) |
| MAC prophylaxisc |
31 (23.3%) |
| Average number of clinic visitsd |
4.75 (1–13) |
| Treated with antibiotic therapyd,e |
40/133 (30.1%) |
| Treated with doxycyclined |
14/133 (10.5%) |
| Hospitalizedd | 7/133 (5.3%) |
aHAART, highly active antiretroviral therapy; OI, opportunistic infection; PCP, Pneumocystis carinii pneumonia; MAC, Mycobacterium avium complex.
bPCP prophylaxis: use of trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine therapy.
cMAC prophylaxis: use of azithromycin or clarithromycin therapy.
dDuring the study period.
eAntibiotics used to treat the ongoing clinical symptoms; persons taking antibiotic therapy specifically for OI prophylaxis alone were not included.
Page created: January 03, 2011
Page updated: January 03, 2011
Page reviewed: January 03, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.